Jimvia Drug Interactions

Sitagliptin is a substrate of P-glycoprotein.
There are no known interactions where it is recommended to avoid concomitant use.
Concurrent use of sitagliptin and insulin secretagogues may result in increased risk of hypoglycemia.
Concurrent use of sitagliptin and digoxin may result in increased digoxin exposure and plasma concentration.
Concurrent use of antidiabetic agents and somatostatin analogues may result in impaired glucose regulation.
Concurrent use of antidiabetic agents and fluoroquinolones may result in changes in blood glucose and increased risk of hypoglycemia or hyperglycemia.
Concurrent use of antidiabetic agents and thioctic acid may result in increased risk of hypoglycemia.
Concurrent use of antidiabetic agents and beta-adrenergic blockers may result in hypoglycemia or hyperglycemia; decreased symptoms of hypoglycemia.
Concurrent use of antidiabetic agents and insulin or pramlintide may result in increased risk of hypoglycemia.
Concurrent use of antidiabetic agents and selected diuretics may result in increased hyperglycemia risk; increased insulin requirement.
Concurrent use of antidiabetic agents and ACE inhibitors may result in increased hypoglycemia risk.